Review of the next generation of Alzheimer's disease therapeutics: Challenges for drug development

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 25, Issue 1, 2001, Pages 27-57

  Cutler, Neal R ^a   Sramek, John J ^a  

^a CALIFORNIA CLINICAL TRIALS   (United States)

Author keywords

AD therapy; Alzheimer's disease; Bridging studies; Clinical trials; Dynabridge

Indexed keywords

ACETYLCHOLINE; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ANTIOXIDANT; ASCORBIC ACID; CHOLINESTERASE INHIBITOR; DONEPEZIL; ESTROGEN; GAMMA SECRETASE; MONOAMINE OXIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROTEIN ANTIBODY; RIVASTIGMINE; SELEGILINE; TACRINE; TAU PROTEIN;

ALZHEIMER DISEASE; CHOLINERGIC SYSTEM; CLINICAL TRIAL; COGNITION; CORRELATION FUNCTION; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; ENZYME ACTIVITY; GASTROINTESTINAL SYMPTOM; GENETIC MARKER; HUMAN; MOLECULAR BIOLOGY; NERVE CELL DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROTRANSMISSION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PROTEIN PHOSPHORYLATION; REVIEW; SYNAPSE;

EID: 0035113305     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(00)00147-0     Document Type: Article

References (118)

1. Alzheimer's and Parkinson's disease. Brain levels of glutathione, glutathione disulfide, and vitamin E
2. A randomized controlled trial of prednisone in Alzheimer's disease
3. Selegiline treatment and the extent of degenerative changes in brain tissue of patients with Alzheimer's disease
4. Inhibition of tau phosphorylating protein kinase cdk5 prevents beta-amyloid-induced neuronal cell death
5. Lithium protects cultured neurons against beta-amyloid induced neurodegeneration
6. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample
7. Cerebrospinal fluid beta-amyloid (1-42) in Alzheimer disease: Differences between early- and late-onset Alzheimer disease and stability during the course of disease
8. Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment
9. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease; results of a placebo-controlled, double-blind, pilot study
10. Incidence of dementia and probable Alzheimer's disease in a general population: The Framingham study
11. The cholinergic hypothesis of geriatric memory dysfunction
12. Expression and regulation of cyclooxygenase-2 in rat microglia
13. Vitamin E protects nerve cells from amyloid beta protein toxicity
14. 17-Beta estradiol protects neurons from oxidative stress-induced cell death in vitro
15. Novel cathepsin D inhibitors block the formation of hyperphosphorylated tau fragments in hippocampus
16. Selegiline for Alzheimer's disease
17. Alpha-2macroglobulin is genetically associated with Alzheimer's disease
18. Tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease?
19. MRI of entorhinal cortex in mild Alzheimer's disease
20. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease
21. Neuropathological staging of Alzheimer-related changes
22. Familial aggregation in Alzheimer's disease: Comparison of risk among relatives of early- and late-onset cases, and among male and female relatives in successive generations
23. 17-beta estradiol enhances the outgrowth and survival of neocortical neurons in culture
24. A case-control study of Alzheimer's disease in Australia
25. Indomethacin and cognitive function in healthy elderly volunteers
26. Specific hippocampal reduction in individuals at risk for Alzheimer's disease
27. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor in patients with mild to moderately severe Alzheimer's disease
28. Alzheimer's disease: A disorder of cortical cholinergic innervation
29. The maximum tolerated dose: An update
30. Clinical study design in dementia: Bridging and dynabridge methodologies
31. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease
32. The effect of education on dementia occurrence in an Italian population with middle to high socioeconomic status
33. A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain
34. Curing amyloidosis: Will it work in humans?
35. Prospects for pharmacological intervention in Alzheimer Disease
36. Pharmacologic and clinicopharmocologic properties of SDZ ENA 713, a centrally selective acetylcholinesterase inhibitor
37. Estimated prevalence of Alzheimer's disease in the United States
38. A controlled trial of tacrine in Alzheimer's disease
39. Observations in a preliminary open trial of estradiol therapy for senile dementia - Alzheimer's type
40. PET and drug research and development
41. Monoamine oxidase B (MOA-B) inhibitor therapy in Parkinson's disease: The degree and reversibility of human brain MAO B inhibition by RO 19 6327
42. PET and the study of drug action in the human brain
43. Pharmacology and efficacy of cyclooxygenase (COX) inhibitors
44. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype
45. Specific domains of β-amyloid from Alzheimer plaques elicit neuron killing in human microglia
46. Secreted forms of beta-amyloid precursor protein protect hippocampal neurons against amyloid beta-peptide-induced oxidative injury
47. Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimer's disease
48. Platelet monoamine oxidase B activity in dementia. A four year follow-up
49. Immunization with β-amyloid: Could T-cell activation have a harmful effect?
50. The presenilins in Alzheimer's disease - Proteolysis holds the key
51. Alzheimer's disease and inflammation: A review of cellular and therapeutic mechanisms
52. Oxygen radicals and the nervous system
53. Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease
54. Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease
55. In vivo effects by estrone sulfate on the central nervous system-senile dementia (Alzheimer's type)
56. Antioxidants prevent amyloid peptide-induced apoptosis and alteration of calcium homeostasis in cultured cortical neurons
57. Elevated levels of tau and ubiquitin in brain and cerebrospinal fluid in Alzheimer's disease
58. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease
59. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment
60. APOE4 associated Alzheimer's risk is modified by α-antichymotrypsin polymorphism
61. Diagnosis of Alzheimer's disease
62. The five-five, ten-ten plan for Alzheimer's disease
63. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease
64. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease
65. Cholinesterase inhibitors: A therapeutic strategy for Alzheimer disease
66. Modulation by DLST of the genetic risk of Alzheimer's disease in a very elderly population
67. Risk of dementia among relatives of Alzheimer's disease patients in the MIRAGE study: What is in store for the oldest old?
68. Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset, confirmed Alzheimer's disease
69. The clinical potential of cyclooxygenase-2-specific inhibitors
70. Phosphorylation of specific sets of tau isoforms reflects different neurofibrillary degeneration processes
71. Indomethacin-induced behavioral changes in an elderly patient with dementia
72. Increased cerebrospinal fluid cAMP levels in Alzheimer's disease
73. Arthritis and antiinflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiological studies
74. Vitamin E concentrations in human brain of patients with Alzheimer's disease, fetuses with Down's syndrome, centenarians and controls
75. Vitamin E and Vitamin C supplement use and risk of incident Alzheimer disease
76. Reduction of β-amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer's disease
77. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease
78. Alzheimer disease: Protective factors
79. Evaluation of estrogen in female patients with dementia of the Alzheimer type
80. Genetic association of the very low density lipoprotein (VLDL) receptor gene with sporadic Alzheimer's disease
81. Differential inhibition of cyclo-oxygenase-1 and -2 by meloxicam and its 4′isomer
82. Genetic polymorphism of cathepsin D is strongly associated with the risk for developing sporadic Alzheimer's disease
83. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration
84. Association of antioxidants with memory in a multiethnic elderly sample using the Third National Health and Nutrition Examination Survey
85. Mild Cognitive Impairment: Clinical characterization and outcome
86. The effect of short-term estrogen replacement therapy on cognition: A randomized, double blind, cross-over trial in postmenopausal women
87. PD98059 prevents neurite degeneration induced by fibrillar beta-amyloid in mature hippocampal neurons
88. Estrogens attenuate neuronal injury due to hemoglobin chemical hypoxia, and excitatory amino acids in murine cortical cultures
89. Dementia in the elderly
90. Low plasma vitamin C in Alzheimer patients despite an adequate diet
91. Epidemiology of clinically diagnosed Alzheimer's disease
92. Donepezil improves cognitive and global function in Alzheimer's disease. A 15-week, double blind, placebo-controlled study
93. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: Final analysis of a US multicentre open-label study
94. Clinical trial of indomethacin in Alzheimer's disease
95. Indomethacin is inappropriate for use in the geriatric population
96. Novel estrogens and their radical scavenging effect, iron-chelating, and total antioxidant activities: 17-alpha-substituted analogs of delta 9(11)-dehydro 17 beta-estradiol
97. Molecular genetics of Alzheimer's disease
98. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease
99. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease
100. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
101. Increased lipoprotein oxidation in Alzheimer's disease
102. Translating cell biology into therapeutic advances in Alzheimer's disease
103. Specific inhibitor for prolyl endopeptidase suppresses the generation of amyloid beta protein in NG108-15 cells
104. The Women's Health Initiative Memory Study (WHIMS): A trial of the effect of estrogen therapy in preventing and slowing the progression of dementia
105. Altered plasma antioxidant status in subjects with Alzheimer's disease and vascular dementia
106. Ongoing trials in Alzheimer's disease
107. Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease
108. Risk of Alzheimer's disease and duration of NSAID use
109. Apolipoprotein E: High avidity binding to b-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease
110. A novel prolyl endopeptidase inhibitor, JTP-4819, with potential for treating Alzheimer's disease
111. Pharmacokinetics and safety of JTP-4819, a novel specific orally active prolyl endopeptidase inhibitor, in healthy male volunteers
112. Inflammatory markers in chronic neurodegenerative disorders with emphasis on Alzheimer's disease
113. Megatrials of hormonal replacement therapy
114. Cyclooxygenase-1 in human Alzheimer and control brain: Quantitative analysis of expression by microglia and CA3 hippocampal neurons
115. Expression of a mitogen-inducible cyclooxygenase in brain neurons: Regulation by synaptic activity and glucocorticoids
116. Estrogen therapy in postmenopausal women
117. Plasma concentration of vitamins A and E and carotenoids in Alzheimer's disease